Triple Therapy Provides Robust and Durable Benefits in Cystic Fibrosis

Triple combination therapy with elexacaftor, ivacaftor, and tezacaftor has advantages over tezacaftor plus ivacaftor in people with cystic fibrosis, according to results of a phase 3b trial.
Reuters Health Information

source https://www.medscape.com/viewarticle/965830?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?